Serum HER-2/NEU decline predicts improved response to trastuzumab-based therapy (serum HER-2/NEU study group)

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Harris, L.
Kostler, W. J.
Lotz, J. P.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Lebanon VA Med Ctr, Lebanon, PA USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Mem Sloan Kettering Canc Ctr, Dept Oncol, New York, NY 10021 USA
[4] Yale Univ, New Haven, CT USA
[5] Univ Hosp Vienna, Div Oncol, Vienna, Austria
[6] Tenon Hosp, Med Oncol Serv, Paris, France
[7] Humboldt Univ, Berlin, Germany
[8] Rene Huguenin Canc Ctr, Paris, France
[9] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [31] Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer
    Petersen, Eva Rabing Brix
    Sorensen, Patricia Diana
    Jakobsen, Erik Hugger
    Madsen, Jonna Skov
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (07) : 1483 - 1492
  • [32] Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton, A
    Mouridsen, H
    Ali, S
    Leitzel, K
    Demers, L
    Harvey, H
    Chaudri-Ross, HA
    Brady, C
    Dugan, M
    Carney, W
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 210 - 210
  • [33] HER-2/neu gene product in serum - An oncoprotein in the diagnosis and therapy of breast carcinoma
    Schulze, G
    ANTICANCER RESEARCH, 2003, 23 (2A) : 1007 - 1010
  • [34] HER-2/neu testing guidelines
    Masood, S
    LABORATORY MEDICINE, 2000, 31 (03) : 129 - 130
  • [35] Her-2/neu and breast cancer
    Kaptain, S
    Tan, LK
    Chen, BY
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2001, 10 (03) : 139 - 152
  • [36] HER-2/neu in bladder carcinoma
    Tommasi, S
    Ditonno, P
    Sisto, MR
    Paradiso, A
    Gentile, A
    Ricco, R
    Schittulli, F
    Jacobellis, U
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (05) : 957 - 961
  • [37] Serum Her-2/neu level predicts disease stage and outcome in men with prostate cancer
    Taneja, SS
    Clute, M
    Shuch, B
    Cheli, CD
    Ghani, F
    Osman, I
    JOURNAL OF UROLOGY, 2004, 171 (04): : 441 - 441
  • [38] Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice
    Jacob, Jennifer
    Radkevich, Olga
    Forni, Guido
    Zielinski, John
    Shim, David
    Jones, Richard F.
    Wei, Wei-Zen
    CELLULAR IMMUNOLOGY, 2006, 240 (02) : 96 - 106
  • [39] Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine
    Dang, Yushe
    Salazar, Lupe G.
    Coveler, Andrew
    Waisman, James
    Higgins, Doreen
    Childs, Jennifer
    Bates, Nicole
    Slota, Meredith
    Disis, Mary L.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [40] Correlation of serum HER-2/neu extracellular domain levels in metastatic breast cancer with the expression of HER-2/neu determined by immunohistochemistry in primary tumors.
    Witzel, I
    Thomssen, C
    Pantel, K
    Neumann, R
    Carney, W
    Loening, T
    Jaenicke, F
    Mueller, V
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S143 - S143
12345